Dashboard
Manage Tickers

KYMR Kymera Therapeutics, Inc.

Nasdaq kymeratx.com


$ 61.76 $ 0.40 (0.65 %)    

Friday, 31-Oct-2025 15:59:58 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 629.18 $ 3.02 (0.48 %)
DIA $ 475.66 $ 0.66 (0.14 %)
SPY $ 682.14 $ 2.23 (0.33 %)
TLT $ 90.33 $ -0.27 (-0.3 %)
GLD $ 368.10 $ -2.01 (-0.54 %)
$ 61.84
$ 60.65
$ 58.20 x 2
$ 62.88 x 1
$ 59.85 - $ 62.24
$ 19.45 - $ 63.96
485,901
na
4.39B
$ 2.17
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-11-2025 06-30-2025 10-Q
2 05-09-2025 03-31-2025 10-Q
3 02-27-2025 01-01-1970 10-K
4 10-31-2024 09-30-2024 10-Q
5 08-07-2024 06-30-2024 10-Q
6 05-02-2024 03-31-2024 10-Q
7 02-22-2024 12-31-2023 10-K
8 11-02-2023 09-30-2023 10-Q
9 08-03-2023 06-30-2023 10-Q
10 05-04-2023 03-31-2023 10-Q
11 02-23-2023 12-31-2022 10-K
12 11-03-2022 09-30-2022 10-Q
13 08-09-2022 06-30-2022 10-Q
14 05-03-2022 03-31-2022 10-Q
15 02-24-2022 12-31-2021 10-K
16 11-10-2021 09-30-2021 10-Q
17 08-06-2021 06-30-2021 10-Q
18 05-06-2021 03-31-2021 10-Q
19 03-11-2021 12-31-2020 10-K
20 11-05-2020 09-30-2020 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

kymera-therapeutics-presents-new-preclinical-data-for-kt-579-oral-irf5-degrader-demonstrating-disease-modifying-activity-across-multiple-immuno-inflammatory-diseases-at-acr-2025
Kymera Therapeutics Presents New Preclinic...
10/27/2025 11:12:09

KT-579, a potent, selective, oral degrader of IRF5, demonstrated broad activity across multiple preclinical models of lupus and...

btig-maintains-buy-on-kymera-therapeutics-raises-price-target-to-75
BTIG Maintains Buy on Kymera Therapeutics,...
10/22/2025 11:34:23

BTIG analyst Jeet Mukherjee maintains Kymera Therapeutics (NASDAQ:KYMR) with a Buy and raises the price target from $59 to ...

mizuho-initiates-coverage-on-kymera-therapeutics-with-outperform-rating-announces-price-target-of-81
Mizuho Initiates Coverage On Kymera Therap...
10/21/2025 12:38:26

Mizuho analyst Joseph Catanzaro initiates coverage on Kymera Therapeutics (NASDAQ:KYMR) with a Outperform rating and announc...

the-analyst-verdict-kymera-therapeutics-in-the-eyes-of-6-experts
The Analyst Verdict: Kymera Therapeutics I...
10/17/2025 18:01:08

citigroup-maintains-buy-on-kymera-therapeutics-raises-price-target-to-80
Citigroup Maintains Buy on Kymera Therapeu...
10/17/2025 15:24:56

Citigroup analyst Geoff Meacham maintains Kymera Therapeutics (NASDAQ:KYMR) with a Buy and raises the price target from $60 ...

oppenheimer-maintains-outperform-on-kymera-therapeutics-raises-price-target-to-63
Oppenheimer Maintains Outperform on Kymera...
10/01/2025 13:37:12

Oppenheimer analyst Jeff Jones maintains Kymera Therapeutics (NASDAQ:KYMR) with a Outperform and raises the price target fro...

truist-securities-maintains-buy-on-kymera-therapeutics-raises-price-target-to-68
Truist Securities Maintains Buy on Kymera ...
09/30/2025 14:32:05

Truist Securities analyst Srikripa Devarakonda maintains Kymera Therapeutics (NASDAQ:KYMR) with a Buy and raises the price t...

hc-wainwright--co-maintains-buy-on-kymera-therapeutics-raises-price-target-to-70
HC Wainwright & Co. Maintains Buy on Kymer...
09/18/2025 13:52:32

HC Wainwright & Co. analyst Andrew S. Fein maintains Kymera Therapeutics (NASDAQ:KYMR) with a Buy and raises the price t...

kymera-advances-oral-stat6-degrader-toward-phase-2b-trials-in-atopic-dermatitis-and-asthma-after-positive-early-data-set-for-late-breaking-presentations-at-major-european-medical-conferences
Kymera Advances Oral STAT6 Degrader Toward...
09/17/2025 11:09:08

Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecul...

barclays-initiates-coverage-on-kymera-therapeutics-with-overweight-rating-announces-price-target-of-60
Barclays Initiates Coverage On Kymera Ther...
09/17/2025 10:53:30

Barclays analyst Etzer Darout initiates coverage on Kymera Therapeutics (NASDAQ:KYMR) with a Overweight rating and announces...

breaking-down-kymera-therapeutics-4-analysts-share-their-views
Breaking Down Kymera Therapeutics: 4 Analy...
09/16/2025 21:01:18

this-chubb-analyst-begins-coverage-on-a-bullish-note-here-are-top-5-initiations-for-tuesday
This Chubb Analyst Begins Coverage On A Bu...
09/16/2025 13:22:50

rbc-capital-initiates-coverage-on-kymera-therapeutics-with-outperform-rating-announces-price-target-of-70
RBC Capital Initiates Coverage On Kymera T...
09/16/2025 13:02:19

RBC Capital analyst Brian Abrahams initiates coverage on Kymera Therapeutics (NASDAQ:KYMR) with a Outperform rating and anno...

kymera-therapeutics-q2-eps-095-misses-084-estimate-sales-11476m-miss-21214m-estimate
Kymera Therapeutics Q2 EPS $(0.95) Misses ...
08/11/2025 11:04:34

Kymera Therapeutics (NASDAQ:KYMR) reported quarterly losses of $(0.95) per share which missed the analyst consensus estimate of...

Core News & Articles
Earnings Scheduled For August 11, 2025
08/11/2025 08:32:28

what-to-expect-from-kymera-therapeuticss-earnings
What to Expect from Kymera Therapeutics's ...
08/08/2025 15:01:29

synovus-financial-gilead-sciences-and-more-on-cnbcs-final-trades
Synovus Financial, Gilead Sciences And Mor...
07/09/2025 12:14:04

Insights from strategists and analysts can greatly influence market sentiment and investment strategies. CNBC's Halftime Re...

oppenheimer-maintains-outperform-on-kymera-therapeutics-lowers-price-target-to-53
Oppenheimer Maintains Outperform on Kymera...
06/27/2025 17:39:25

Oppenheimer analyst Jeff Jones maintains Kymera Therapeutics (NASDAQ:KYMR) with a Outperform and lowers the price target fro...

reported-earlier-kymera-therapeutics-prices-public-offering-of-5044500-shares-at-44-and-655500-pre-funded-warrants-at-439999-to-raise-2508m
Reported Earlier, Kymera Therapeutics Pric...
06/27/2025 06:12:49

wells-fargo-maintains-overweight-on-kymera-therapeutics-lowers-price-target-to-53
Wells Fargo Maintains Overweight on Kymera...
06/26/2025 14:19:14

Wells Fargo analyst Derek Archila maintains Kymera Therapeutics (NASDAQ:KYMR) with a Overweight and lowers the price target ...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION